- Home
- ASLE vs SNY Comparison
ASLE vs SNY Comparison
Compare ASLE & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASLE | SNY |
|---|---|---|
| Founded | 2008 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.0M | 119.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ASLE | SNY |
|---|---|---|
| Price | $7.07 | $48.43 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $7.00 | ★ $61.50 |
| AVG Volume (30 Days) | 327.0K | ★ 2.5M |
| Earning Date | 11-06-2025 | 01-29-2026 |
| Dividend Yield | N/A | ★ 3.30% |
| EPS Growth | N/A | ★ 105.93 |
| EPS | 0.11 | ★ 8.67 |
| Revenue | $339,090,000.00 | ★ $53,890,648,839.00 |
| Revenue This Year | $1.35 | $1.73 |
| Revenue Next Year | $19.09 | $6.49 |
| P/E Ratio | $63.55 | ★ $10.94 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.56 | $44.62 |
| 52 Week High | $9.12 | $60.12 |
Technical Indicators
Market Signals| Indicator | ASLE | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 58.93 | 46.32 |
| Support Level | $6.86 | $48.16 |
| Resistance Level | $7.27 | $48.74 |
| Average True Range (ATR) | 0.17 | 0.64 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 68.94 | 65.42 |
Price Performance
Historical ComparisonAbout ASLE AerSale Corporation
AerSale Corp is an integrated, diversified leader in aviation aftermarket products and services. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing a broad range of maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. The company operating segment includes Asset Management Solutions and TechOps. It generates maximum revenue from the Asset Management Solutions segment.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.